Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791479 · ClinicalTrials.gov registry record · Phase 2
Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00791479: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00791479 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 167 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00791479, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.
Primary Outcome
Least Squares (LS) means of change from baseline for glycosylated hemoglobin (HbA1c) were calculated using mixed model repeated measures (MMRM) with pre-study therapy, country, dose, visit, and dose-by-visit interaction as fixed effects and baseline HbA1c as covariate.
Interventions
- DRUG LY2189265 and Lifestyle Measures
- DRUG Placebo solution and Lifestyle Measures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00791479 record still lists
NCT00791479 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% higher).
The record links to 0 conditions, and to 2 interventions - of which LY2189265 and Lifestyle Measures is the first listed.
NCT00791479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00791479 about?
NCT00791479 is a clinical study titled "Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes". This is a study to demonstrate that different doses of once-weekly LY2189265 injected subcutaneously will have dose proportional effect on hemoglobin A1c (HbA1c) at 12 weeks in participants with type 2 diabetes mellitus.
What is the current status of trial NCT00791479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2008-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00791479?
The interventions under investigation include: LY2189265 and Lifestyle Measures (DRUG), Placebo solution and Lifestyle Measures (DRUG).
Who is sponsoring clinical trial NCT00791479?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00791479's enrollment target sits among peer trials
167 406th of 2000 higher than 1,595 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia